CL2022001245A1 - Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr - Google Patents
Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftrInfo
- Publication number
- CL2022001245A1 CL2022001245A1 CL2022001245A CL2022001245A CL2022001245A1 CL 2022001245 A1 CL2022001245 A1 CL 2022001245A1 CL 2022001245 A CL2022001245 A CL 2022001245A CL 2022001245 A CL2022001245 A CL 2022001245A CL 2022001245 A1 CL2022001245 A1 CL 2022001245A1
- Authority
- CL
- Chile
- Prior art keywords
- conditions mediated
- heteroarylaminosulfonamides
- membered
- cftr activity
- treat conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934293P | 2019-11-12 | 2019-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001245A1 true CL2022001245A1 (es) | 2023-03-10 |
Family
ID=73740547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001245A CL2022001245A1 (es) | 2019-11-12 | 2022-05-12 | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240002374A1 (https=) |
| EP (1) | EP4058439A1 (https=) |
| JP (2) | JP7721517B2 (https=) |
| KR (1) | KR20220115829A (https=) |
| CN (1) | CN115003659B (https=) |
| AU (1) | AU2020384279A1 (https=) |
| BR (1) | BR112022009185A2 (https=) |
| CA (1) | CA3158057A1 (https=) |
| CL (1) | CL2022001245A1 (https=) |
| CO (1) | CO2022007953A2 (https=) |
| EC (1) | ECSP22046050A (https=) |
| IL (1) | IL292966A (https=) |
| JO (1) | JOP20220105A1 (https=) |
| MX (1) | MX2022005809A (https=) |
| PE (1) | PE20221461A1 (https=) |
| PH (1) | PH12022551139A1 (https=) |
| WO (1) | WO2021097057A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019222758B2 (en) | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| EP4058434A1 (en) | 2019-11-12 | 2022-09-21 | Genzyme Corporation | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity |
| WO2022076628A1 (en) * | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN113480416B (zh) * | 2021-07-12 | 2023-03-21 | 重庆大学 | 一种芳基酮的制备方法 |
| KR20240168370A (ko) | 2022-03-30 | 2024-11-29 | 이시하라 산교 가부시끼가이샤 | 피리다지논계 화합물 또는 그의 염 및 그들을 함유하는 유해 생물 방제제 |
| CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
| EP4611742A1 (en) | 2022-10-31 | 2025-09-10 | Sionna Therapeutics Inc. | Methods of treating cftr-mediated diseases or disorders |
| WO2025017207A1 (en) * | 2023-07-20 | 2025-01-23 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Inhibitors of smndc1 and their therapeutic use |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992015570A1 (en) * | 1991-03-07 | 1992-09-17 | Hisamitsu Pharmaceutical Co., Inc. | Novel diphenylthyazole derivative |
| US5856347A (en) * | 1994-11-29 | 1999-01-05 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
| JP2005510508A (ja) * | 2001-11-08 | 2005-04-21 | 藤沢薬品工業株式会社 | アデノシンアンタゴニストとしてのチアゾールピリダジノン類 |
| ZA200602755B (en) | 2003-09-06 | 2007-06-27 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| RU2014100111A (ru) | 2011-06-10 | 2015-07-20 | МЕДИММЬЮН, ЭлЭлСи | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ |
| WO2016183173A1 (en) * | 2015-05-12 | 2016-11-17 | Avista Pharma Solutions | Antiparasitic compounds |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| EP4611742A1 (en) * | 2022-10-31 | 2025-09-10 | Sionna Therapeutics Inc. | Methods of treating cftr-mediated diseases or disorders |
-
2020
- 2020-11-12 CN CN202080092755.2A patent/CN115003659B/zh active Active
- 2020-11-12 BR BR112022009185A patent/BR112022009185A2/pt unknown
- 2020-11-12 MX MX2022005809A patent/MX2022005809A/es unknown
- 2020-11-12 AU AU2020384279A patent/AU2020384279A1/en active Pending
- 2020-11-12 JP JP2022527081A patent/JP7721517B2/ja active Active
- 2020-11-12 KR KR1020227019502A patent/KR20220115829A/ko active Pending
- 2020-11-12 PH PH1/2022/551139A patent/PH12022551139A1/en unknown
- 2020-11-12 IL IL292966A patent/IL292966A/en unknown
- 2020-11-12 WO PCT/US2020/060180 patent/WO2021097057A1/en not_active Ceased
- 2020-11-12 CA CA3158057A patent/CA3158057A1/en active Pending
- 2020-11-12 PE PE2022000772A patent/PE20221461A1/es unknown
- 2020-11-12 EP EP20820656.5A patent/EP4058439A1/en active Pending
-
2022
- 2022-05-10 JO JOP/2022/0105A patent/JOP20220105A1/ar unknown
- 2022-05-11 US US17/742,169 patent/US20240002374A1/en active Pending
- 2022-05-12 CL CL2022001245A patent/CL2022001245A1/es unknown
- 2022-06-03 CO CONC2022/0007953A patent/CO2022007953A2/es unknown
- 2022-06-09 EC ECSENADI202246050A patent/ECSP22046050A/es unknown
-
2025
- 2025-07-30 JP JP2025126773A patent/JP2025160375A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022005809A (es) | 2022-06-08 |
| WO2021097057A1 (en) | 2021-05-20 |
| PE20221461A1 (es) | 2022-09-21 |
| JP2025160375A (ja) | 2025-10-22 |
| EP4058439A1 (en) | 2022-09-21 |
| KR20220115829A (ko) | 2022-08-18 |
| JOP20220105A1 (ar) | 2023-01-30 |
| AU2020384279A1 (en) | 2022-05-26 |
| IL292966A (en) | 2022-07-01 |
| CN115003659A (zh) | 2022-09-02 |
| CN115003659B (zh) | 2026-04-21 |
| BR112022009185A2 (pt) | 2022-07-26 |
| JP7721517B2 (ja) | 2025-08-12 |
| CO2022007953A2 (es) | 2022-09-09 |
| US20240002374A1 (en) | 2024-01-04 |
| ECSP22046050A (es) | 2022-08-31 |
| CA3158057A1 (en) | 2021-05-20 |
| PH12022551139A1 (en) | 2023-07-17 |
| JP2023500408A (ja) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007953A2 (es) | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr | |
| CO2022007946A2 (es) | Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente | |
| CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| JOP20240037A1 (ar) | مركبات الإندول وطرق الاستخدام | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| CY1125488T1 (el) | Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6 | |
| EP4374851A3 (en) | Ophthalmic composition for treatment of dry eye disease | |
| WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| EP4252755A3 (en) | Therapeutic compounds | |
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| MX2021007032A (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos. | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| DOP2021000028A (es) | Formulaciones de dendrímeros | |
| CO2025000163A2 (es) | Compuestos, composiciones y métodos de uso de los mismos | |
| WO2018067638A3 (en) | High mobility group b1 protein inhibitors | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| EA202090298A1 (ru) | Способы лечения муковисцидоза | |
| EA202092013A1 (ru) | Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6 |